25. 進行性多巣性白質脳症 Progressive multifocal leukoencephalopathy Clinical trials / Disease details


臨床試験数 : 26 薬物数 : 35 - (DrugBank : 22) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 37

  
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000022151
2016/04/3030/04/2016The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathyThe efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy - The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathymefloquine is to be taken orally 275mg for 3days then 275mg weekly for 6 manthsDepartment of Neurology, Shimane University HospitalNULLComplete: follow-up complete20years-oldNot applicableMale and Female5Not selectedJapan
2JPRN-UMIN000023752
2016/04/1424/08/2016Medication with mefloquine hydrochloride for progressive multifocal leukoencephalopathy (PML) out of the application range of insuranceMedication with mefloquine hydrochloride for progressive multifocal leukoencephalopathy (PML) out of the application range of insurance - Medication with mefloquine hydrochloride for progressive multifocal leukoencephalopathy (PML) out of the application range of insurance progressive multifocal leukoencephalopathyOral mefloquine hydrochloride 275mg once a day at first 3 days.
Since second week, 275mg in each week oral intake until 6 months
Nagoya City UniversityNULLComplete: follow-up completeNot applicableNot applicableMale and Female1Not applicableJapan
3EUCTR2008-001314-24-IT
(EUCTR)
15/01/200919/03/2009A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) - NDA Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) - ND Progressive Multifocal Leukoencephalopathy (PML)
MedDRA version: 9.1;Level: LLT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy
Trade Name: Lariam
INN or Proposed INN: Mefloquine
BIOGEN IDEC LTDNULLNot RecruitingFemale: yes
Male: yes
40United Kingdom;France;Spain;Italy
4EUCTR2008-001314-24-GB
(EUCTR)
02/01/200928/05/2008A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) Progressive Multifocal Leukoencephalopathy (PML)
MedDRA version: 9.1;Level: LLT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy
Trade Name: Lariam
Product Name: Mefloquine
Product Code: 111JC101
INN or Proposed INN: MEFLOQUINE
Biogen Idec LtdNULLNot RecruitingFemale: yes
Male: yes
60United Kingdom;France;Spain;Italy
5NCT00746941
(ClinicalTrials.gov)
January 20093/9/2008Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects With Progressive Multifocal Leukoencephalopathy (PML)Progressive Multifocal LeukoencephalopathyDrug: mefloquineBiogenElan PharmaceuticalsTerminated18 Years75 YearsAll37Phase 1/Phase 2United States;Brazil;Germany;Italy;Spain;Australia;France;Puerto Rico;United Kingdom
6EUCTR2008-001314-24-ES
(EUCTR)
19/11/200811/07/2008A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)Estudio aleatorizado con evaluador en condiciones de ciego para explorar el efecto de mefloquina en sujetos con leucoencefalopatía multifocal progresiva (LMP)A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)Estudio aleatorizado con evaluador en condiciones de ciego para explorar el efecto de mefloquina en sujetos con leucoencefalopatía multifocal progresiva (LMP) Progressive Multifocal Leukoencephalopathy (PML)Leucoencefalopatía Multifocal Progresiva (LMP)
MedDRA version: 9.1;Level: LLT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy
Trade Name: Lariam
Product Name: Mefloquine
Product Code: 111JC101
INN or Proposed INN: MEFLOQUINE
Biogen Idec LtdNULLNot RecruitingFemale: yes
Male: yes
40Phase 2France;Spain;Italy;United Kingdom
7EUCTR2008-001314-24-FR
(EUCTR)
22/10/200823/07/2008A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) Progressive Multifocal Leukoencephalopathy (PML)
MedDRA version: 9.1;Level: LLT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy
Trade Name: Lariam
Product Name: Mefloquine
Product Code: 111JC101
INN or Proposed INN: MEFLOQUINE
Biogen Idec LtdNULLNot RecruitingFemale: yes
Male: yes
40Phase 2France;Spain;Italy;United Kingdom